miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

NatWest cuts mortgage costs ahead of spring statement

View original at uk.finance.yahoo.com
NatWest cuts mortgage costs ahead of spring statement NatWest has cut borrowing costs this week as most lenders adopted a wait-and-see approach ahead of the spring statement that is due on 3 March…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • It is widely expected that no major housing reforms will be announced in Rachel Reeves's statement

    80% confidence

  • Consumer prices rose 3% in the year to January, down from 3.4% in December

    80% confidence

  • The change was part of a reprice following the changes to swaps after the Bank of England held interest rates

    80% confidence

  • Average five-year fixed deal came in at 4.99%, up from the previous 4.94%

    80% confidence

  • It marks the lowest reading for the Consumer Price Index since March last year

    80% confidence

  • Financial markets are pricing in a 0.25 percentage point reduction in the Bank of England's base rate to 3.5% at its meeting on 19 March

    80% confidence

  • Average rate for two-year fixed mortgage came in at 4.75% this week, higher than last week's 4.53%

    80% confidence

Data points we hold from this source

Barclays · five year fixed mortgage rate4.00 percent
Barclays · two year fixed mortgage rate3.70 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
NatWest cuts mortgage costs ahead of spring statement — Source | Via News | es.VIA.NEWS